@article{TCR12644,
author = {Trever G. Bivona},
title = {Dividing and conquering the variation among variants in EML4-ALK lung cancer},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 2},
year = {2017},
keywords = {},
abstract = {Activating gene rearrangements in the anaplastic lymphoma kinase are present in approximately 2–7% of lung adenocarcinomas (ALK + cancers) (1,2). Patients with ALK + lung adenocarcinoma often benefit from treatment with an ALK tyrosine kinase inhibitor (TKI), such as crizotinib, ceritinib, and alectinib (2). However, acquired ALK TKI resistance remains an obstacle to long-term patient survival in patients who do respond to initial therapy and a distinct subset of ALK + patients fails to experience an initial tumor regression, exhibiting intrinsic resistance (2). Identifying the basis of both innate and acquired resistance is essential to improve clinical outcomes.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/12644}
}